Study reveals new mechanism that might promote cancer's growth and spread in the body

July 10, 2012

Researchers have discovered a previously unknown mechanism that promotes the growth and spread of cancer. The mechanism involves key immune cells and a new role for small regulatory molecules called microRNA. The findings suggest a new strategy for treating cancer and perhaps diseases of the immune system.

Tiny vesicles released by tumors cells are taken up by healthy immune cells, causing the immune cells to discharge chemicals that foster cancer-cell growth and spread, according to a study by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and at Children's Hospital in Los Angeles.

The study uses lung cancer cells to show that the vesicles contain potent regulatory molecules called microRNA, and that the uptake of these molecules by immune cells alters their behavior. The process in humans involves a fundamental receptor of the immune system called Toll-like receptor 8 (TLR8).

The findings, published in the early edition of the Proceedings of the National Academy of Sciences, suggest a new strategy for treating cancer and diseases of the immune system, the researchers say, and a new role for microRNA in the body.

"This study reveals a new function of microRNA, which we show binds to a protein receptor," says principal investigator Dr. Carlo Croce, director of Ohio State's Human Cancer Genetics program and a member of the OSUCCC – James Molecular Biology and Cancer Genetics program. "This tells us that some cancer-released microRNAs can bind and activate a receptor in a hormone-like fashion, and this has not been seen before."

MicroRNAs help control the type and amount of proteins that cells make, and they typically do this by binding with the messenger-RNA that encodes a protein.

"In this study we discovered a completely new mechanism used by cancer to grow and spread, therefore we can develop new drugs that fight tumors by entering this newly identified breach in 's fortress," says co-corresponding author and first author Dr. Muller Fabbri, assistant professor of Pediatrics and Molecular Biology and Immunology at the Keck School of Medicine of the University of Southern California.

"Equally exciting, we show that this mechanism involves a fundamental receptor of the , TLR8, suggesting that the implications of this discovery may extend to other diseases such as autoimmune and inflammatory diseases," Fabbri says.

Key findings of the study include the following:

  • Lung tumor cells secrete microRNA-21 and microRNA-29a in called exosomes, and these exosomes are taken up by called macrophages located where tumor tissue abuts normal tissue.
  • In human macrophages, microRNA-29a and microRNA-21 bind with TLR8, causing the macrophages to secrete -necrosis-factor alpha and interleukin-6, two cytokines that promote inflammation.
  • Increased levels of the two cytokines were associated with an increase in the number of tumors per lung in an animal model, while a drop in those levels led to a drop in the number per lung, suggesting that they also play a role in metastasis.

Explore further: How early breast tumors become deadly: A small group of molecules might hold the answer

Related Stories

How early breast tumors become deadly: A small group of molecules might hold the answer

February 7, 2012
Researchers have discovered a restricted pattern of molecules that differentiate early-stage breast tumors from invasive, life-threatening cancer. They also found a similar molecular signature that correlated with the aggressiveness ...

Study reveals how normal cells fuel tumor growth

December 21, 2011
A new study published in the journal Nature Cell Biology has discovered how normal cells in tumors can fuel tumor growth.

miR loss may power maligant transformation in chronic leukemia

July 5, 2012
Loss of a particular microRNA in chronic lymphocytic leukemia shuts down normal cell metabolism and turns up alternative mechanisms that enable cancer cells to produce the energy and build the molecules they need to proliferate ...

Study reveals mechanism of lung-cancer drug resistance

January 19, 2012
New research published in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.